Patents by Inventor Murugaiah Andappan Murugaiah Subbaiah

Murugaiah Andappan Murugaiah Subbaiah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230348468
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: November 2, 2023
    Inventors: Matthew COX, Naidu S. CHOWDARI, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Christine M. TARBY, Yam B. POUDEL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20230167082
    Abstract: There are disclosed prodrugs of the compounds of the formula. The prodrugs are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: July 14, 2020
    Publication date: June 1, 2023
    Inventors: Ryan M. Moslin, David S. Weinstein, Thangeswaran Ramar, Murugaiah Andappan Murugaiah Subbaiah
  • Publication number: 20230144824
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 11, 2023
    Inventors: Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Qiang CONG, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Christine M. TARBY, Patrice GILL, Andrew F. DONNELL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20230127326
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Qiang CONG, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Patrice GILL, Prasanna SIVAPRAKASAM, Walter L. JOHNSON, Murugaiah Andappan Murugaiah SUBBAIAH, Yam B. POUDEL
  • Publication number: 20230131192
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Matthias BROEKEMA, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Naidu S. CHOWDARI, Walter L JOHNSON, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20230118688
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Inventors: Heng CHENG, Christine M. TARBY, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Walter L. JOHNSON, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Patrice GILL, Andrew F. DONNELL, Murugaiah Andappan Murugaiah SUBBAIAH
  • Publication number: 20230122249
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Daniel O'MALLEY, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Prasanna SIVAPRAKASAM, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH,Murugaiah
  • Patent number: 11618753
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 4, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Publication number: 20230041738
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: February 9, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Mathias BROEKEMA, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20220315580
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: December 9, 2020
    Publication date: October 6, 2022
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Patent number: 11447449
    Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, David K. Williams, Murugaiah Andappan Murugaiah Subbaiah
  • Publication number: 20220213099
    Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV): or salts thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using the compounds as prodrugs of an inhibitor of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These prodrugs compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Alaric J. DYCKMAN, Murugaiah Andappan Murugaiah Subbaiah
  • Publication number: 20210070698
    Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.
    Type: Application
    Filed: January 3, 2019
    Publication date: March 11, 2021
    Inventors: James Aaron BALOG, Steven P. SEITZ, David K. WILLIAMS, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Patent number: 10913738
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Publication number: 20200347071
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Application
    Filed: January 24, 2019
    Publication date: November 5, 2020
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Publication number: 20190389859
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: February 12, 2018
    Publication date: December 26, 2019
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Patent number: 9499482
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: November 22, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: William N. Washburn, Murugaiah Andappan Murugaiah Subbaiah, Saleem Ahmad
  • Publication number: 20150218092
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.
    Type: Application
    Filed: September 3, 2013
    Publication date: August 6, 2015
    Inventors: William N. Washburn, Murugaiah Andappan MuruGaiah Subbaiah, Saleem Ahmad
  • Patent number: 8357710
    Abstract: There is provided a compound of formula I, wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: January 22, 2013
    Assignee: Vicore Pharma AB
    Inventors: Mathias Alterman, Anders Hallberg, Murugaiah Andappan Murugaiah Subbaiah
  • Publication number: 20090069382
    Abstract: There is provided a compound of formula I, wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Application
    Filed: April 12, 2006
    Publication date: March 12, 2009
    Inventors: Mathias Alterman, Anders Hallberg, Murugaiah Andappan Murugaiah Subbaiah